| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566290 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9566289 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9549938 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
| US9572823 | ANACOR PHARMS INC | Boron-containing small molecules |
Feb, 2026
(1 year, 9 months from now) | |
|
US9549938 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9566290 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9572823 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
|
US9566289 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Aug, 2026
(2 years from now) | |
| US7767657 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
| US7582621 | ANACOR PHARMS INC | Boron-containing small molecules |
May, 2027
(3 years from now) | |
|
US7582621 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Nov, 2027
(3 years from now) | |
Kerydin is owned by Anacor Pharms Inc.
Kerydin contains Tavaborole.
Kerydin has a total of 11 drug patents out of which 0 drug patents have expired.
Kerydin was authorised for market use on 07 July, 2014.
Kerydin is available in solution;topical dosage forms.
Kerydin can be used as treatment for onychomycosis that is tinea unguium, treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes, treatment of onychomycosis of a toenail.
Drug patent challenges can be filed against Kerydin from 07 January, 2019.
The generics of Kerydin are possible to be released after 26 November, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2019 |
| Pediatric Exclusivity(PED) | Jan 07, 2020 |
Drugs and Companies using TAVABOROLE ingredient
NCE-1 date: 07 January, 2019
Market Authorisation Date: 07 July, 2014
Treatment: Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail; Treatment for onychomycosis that is tinea unguium
Dosage: SOLUTION;TOPICAL
KERYDIN family patents
